Interní Med. 2007; 9(7): 352-354

Možnosti inzulinové léčby diabetu typu 2 bazálním analogem detemir

MUDr. Svatopluk Solař
JIP, oddělení gastroenterologie, hepatologie a metabolizmu, Interní klinika 1. LF UK a ÚVN, Praha

Diabetes mellitus 2. typu (dále DM T2) je chronické, progresivní, polygenní onemocnění s celosvětově významně narůstající incidencí a s častým výskytem dalších rizikových onemocnění, které urychlují proces aterosklerózy. Zmiňovaná vzrůstající incidence, obtížná časná diagnostika a úskalí komplexní nefarmakologické a farmakologické léčby jsou nejčastějšími důvody vysoké morbidity a mortality diabetiků 2. typu (6, 11). Jednou z možností, jak tento nepříznivý trend ovlivnit, je využití nových léčebných postupů, kam lze zařadit i bazální analogový inzulin detemir.

Keywords: diabetes typu 2, léčba inzulinem, analogový bazální inzulin detemir

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Solař S. Možnosti inzulinové léčby diabetu typu 2 bazálním analogem detemir. Interní Med. 2007;9(7):352-354.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. DeVries JK, et al. Refining basal unsulin therapy: what have we learned in the age of analogues? Diabetes Metabolism Research&Reviews 2007. Go to original source...
    2. Dornhorst A et al. Safety and efficacy of insulin detemir in clinical practice: 14week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007; 61: 523-528. Go to original source... Go to PubMed...
    3. Hermansen K, et al. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007; 9 (3): 209-217. Go to original source... Go to PubMed...
    4. Klein O, et al. Albumin bound basal insulin analogues (insulin detemir and NN 344): Comparable time-action profiles, but less variability than glargine in type 2 diabetes. Diabetes, Obesity and Metabolism 2006. Go to original source... Go to PubMed...
    5. Luddeke HJ, Sreenan S, et al, PREDICTIVE Study Group. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes, baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007; 9: 428-434. Go to original source... Go to PubMed...
    6. Muggeo M, et al, Diabetes Care 2006.
    7. Philis-Tsimikas, et al. Comparison of once daily insulin detemir added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther., 2006; 28 (10). Go to original source... Go to PubMed...
    8. Raslova T, et al. Insulin detemir results in less weight gain than NPH insulin when in basal-bolus therapy for type 2 diabetes mellitus. Clin Drug Investig. 2007; 27 (4): 279-285. Go to original source... Go to PubMed...
    9. SPC Levemir, 2007.
    10. Standard léčby diabetu 2. typu, Česká diabetologická společnost, Výbor 2007-08-16.
    11. Stratton IM, Adler AI, et al. Association of glycaemia with macrovascular and microvascular complications of type diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (17258): 405-412. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.